Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted.

Key Data Concepts:   

? These are the company names, stock quotes, topics, and entities related to this data.

000423 002737 300111 300170 300713 Beijing Tongrentang Dong-E-E-Jiao Hand Enterprise Solutions Harbin Pharmaceutical Group Shenzhenrease Technology Sunflower Pharmaceutical Group Tianjin Zhongxin Pharmaceutical Group Corporation Zhangzhou Pientzehuang Pharmaceutical Zhejiang Sunflower Great Health Limited Liability Company Regulations Human Resources Management Strategy, Marketing Annual, Special Corporate Meeting Annual Report Board Of Directors Patent, Copyright, Trademark Research, Development Health, Beauty Product Pharmaceutical Financial, Business Service Insurance Manufacturing, Engineering Prices Market, Exchange Securities Diseases, Conditions Medicine Health Insurance Social Security Series Cosmetics Economy, Business, Finance Health

Full Data

?
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets

Join Now!

Need this critical market data?

Access thousands of market events, data points, and news articles!

Already have an account?
Login

Home » News » Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted.